The Contagion® Zoonotic & Vector-borne Diseases specialty page provides zoonotic & vector-borne disease-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
A phase 1 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases will test the safety and effectiveness of monoclonal antibody CIS43LS used as prophylaxis against malaria.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512